Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 116

Therapies Disease Engineering Medical Schools 116

Drug Target Review

JANUARY 15, 2024

As T cells develop, chromosomal DNA encoding the TCR of the CD8 T cells of each individual is rearranged and ‘educated’ to respond only to peptides presented in the context of a specific HLA Class I molecule present in that individual. References Robinson R, McMurran C, McCully M, Cole D. Engineering soluble T-cell receptors for therapy.

Engineering 110

Engineering DNA Virus Immune Response 110

The Pharma Data

SEPTEMBER 1, 2020

Despite a number of treatments on the market, 40% of adults with the disease in the UK fail to achieve target blood sugar of ?7%, 7%, increasing the risk of diabetes-related complications and underscoring the need for new strategies.

Medical Schools 52

Medical Schools Treatment Clinical Development Disease 52

The Pharma Data

NOVEMBER 1, 2020

Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drug. Trial facilitated with coll a boration of Harvard Medical School and one of the world’s top Neurologist, Dr. Howard Weiner. Clinical Data Expected by End of Year.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

JANUARY 7, 2021

08, 2021 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc. , Compelling responses at this stage of disease are rare and lack durability.

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

The Pharma Data

APRIL 12, 2022

Currently, available therapies do not address the underlying disease biology and have not shown a consistent effect on both biomarkers of disease modification and overall survival. Disease control with reversal of bone marrow fibrosis is a key objective for improving patient outcomes,” said Mohamed Zaki, M.D., Garcia, M.D.,

Medical Schools 52

Medical Schools Trials Disease Clinical Development 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

MARCH 17, 2021

percent compared to ET alone – a statistically significant improvement in invasive disease-free survival for HR+, HER2- high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009). Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute. About Verzenio® (abemaciclib). had Grade 3 or 4, and 0.4%

Trials 52

Trials Therapies Treatment Disease 52

The Pharma Data

OCTOBER 15, 2020

Sabbagh will be responsible for expanding Inozyme’s proprietary pipeline by identifying and developing new therapeutics for monogenic and non-genetic diseases of abnormal mineralization. Prior to joining Inozyme, Sabbagh served as the head of rare renal and musculoskeletal diseases research at Sanofi.

Pharmaceuticals 52

Pharmaceuticals Clinical Pharmacology Medical Schools Therapies 52

Drug Target Review

DECEMBER 28, 2023

Patients with high numbers of clonal neoantigens show improved disease-free survival. Sergio co-led the development of a first-in-class Treg-depleting anti-human CD25 antibody with TUSK Therapeutics, which was acquired by Roche in 2018 and is currently under clinical evaluation.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

JANUARY 24, 2021

A key advantage of Elasmogen’s VNAR platform is the ability to bind to their target at sites that are inaccessible to human antibodies translating, in many cases, to increased potency and specificity against the disease. We then screened these for VNAR binders that block viral infection, and are delighted with the outcomes.”

Research 40

Research Virus Medical Schools Government 40

Drug Target Review

MARCH 20, 2025

Its one of the most common heart rhythm disorders and can be caused by conditions like high blood pressure and heart disease, or can sometimes occur without an obvious cause. Managing AFib often involves medication, lifestyle changes, and occasionally procedures to restore a normal heart rhythm.

Therapies 52

Therapies Trials Clinical Development FDA 52